AChE Substrate, 2 vials
- Known as:
- AChE Substrate, 2 vials
- Catalog number:
- C047-1EA
- Product Quantity:
- 1
- Category:
- -
- Supplier:
- Arbor
- Gene target:
- AChE Substrate 2 vials
Related genes to: AChE Substrate, 2 vials
- Gene:
- ACHE NIH gene
- Name:
- acetylcholinesterase (Cartwright blood group)
- Previous symbol:
- YT
- Synonyms:
- -
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-02
- Date modifiied:
- 2019-04-23
Related products to: AChE Substrate, 2 vials
Related articles to: AChE Substrate, 2 vials
- The amyloid cascade hypothesis provided a compelling rationale for Alzheimer's disease (AD) drug development, but many amyloid-β (Aβ)-targeted agents failed to show benefit. The present review article evaluated emerging Aβ-directed therapies, focusing on mechanisms, clinical efficacy, safety, and regulatory progress. - Source: PubMed
Publication date: 2026/06/20
Lozupone MadiaDibello VittorioSardone RodolfoZupo RobertaCastellana FabioBortone IlariaLampignano LuisaDi Matteo MichelaMoramarco GiuseppeDellegrazie FloraDaniele AntonioSolfrizzi VincenzoPanza Francesco - Hemifacial microsomia (HFM) is a congenital craniofacial malformation characterized by unilateral hypoplasia of structures derived from the first and second pharyngeal arches. Although the phenotype is well described, the underlying etiology remains incompletely understood. Disturbances in embryonic vascular development have long been proposed as a potential mechanism contributing to the characteristic unilateral craniofacial phenotype. - Source: PubMed
Jacobs KarlBaramakeh Aaryavan der Meer HedwigKorfage Hansde Bakker BernadetteLangenbach GeerlingOostra Roelof JanLobbezoo Frank - - Source: PubMed
Publication date: 2026/06/22
Scardina BrookeWeppner Justin - Tapentadol is a dual mechanism analgesic utilizing both μ-opioid receptor (MOR) agonism and norepinephrine reuptake inhibition (NRI). This study evaluated the pharmacokinetics and pharmacodynamics of tapentadol as a potential analgesic with the goal of treating pain in horses. Pharmacokinetics of both tapentadol and tapentadol-O-glucuronide were elucidated. Six horses received three separate escalating single oral doses (1, 3, and 5 mg/kg) and a single intravenous (0.32 mg/kg) dose of tapentadol in a four-period sequential design. Concentrations of tapentadol and tapentadol-O-glucuronide were determined using liquid chromatography-tandem mass spectrometry. The maximum concentrations (mean ± SD) in plasma following administration of 1, 3, 5 mg/kg oral tapentadol were 7.98 ± 6.95, 39.8 ± 53.8, and 210.6 ± 234.4 ng/mL at 0.75, 0.63, and 0.38 h, respectively. Maximum plasma concentration (mean ± SD) after a single 0.32 mg/kg IV dose was 339.2 ± 83.5 ng/mL. The maximum concentrations of tapentadol-O-glucuronide following single 1, 3, and 5 mg/kg oral doses and a single 0.32 mg/kg IV dose of tapentadol were 532.6 ± 171.4, 1169.4 ± 345.4, 1559.5 ± 574.6, and 226.4 ± 51.5 ng/mL at times 6.0, 6.0, 7.0, and 0.5 h. Tapentadol was well-tolerated at all doses. - Source: PubMed
Publication date: 2026/06/20
Lynch Annabella DMama Khursheed RMcKemie Dan SKass Phillip HKnych Heather K - HPV infection is a major contributor to cervical and other anogenital cancers, with people living with HIV (PLWH) at particularly high risk due to persistent infection. Although prophylactic HPV vaccines are widely used and generally safe, their efficacy and safety in PLWH remain uncertain. - Source: PubMed
Publication date: 2026/06/20
Neto Antonio Alves de SouzaSouza Amaxsell Thiago Barros deSarmento Ayane Cristine AlvesGonçalves Ana KatherineAdedipe Tolude Medeiros Kleyton SantosCrispim Janaina Cristiana de Oliveira